Max Robotics — Global Service Robot Directory + US Certification

About

Dr. Shuji Isotani is a pioneering robotic surgeon whose work has fundamentally advanced the precision and outcomes of urologic oncology. His research centers on the intersection of advanced robotics, three-dimensional virtual surgical planning, and patient-reported outcomes for prostate and kidney cancers. Dr. Isotani’s major contributions include demonstrating the feasibility and accuracy of virtual partial nephrectomy analysis, a technique that uses color-coded 3D models to predict surgical outcomes for renal tumors—a study that has garnered 41 citations. He has also significantly impacted prostate cancer care by identifying that urethral length measured by MRI is a key predictor of urinary continence recovery after robot-assisted radical prostatectomy, a finding cited 37 times. His work extends to assessing health-related quality of life using the Expanded Prostate Cancer Index Composite, and he has reported on the safe application of robotic partial nephrectomy in rare anatomical conditions like situs inversus totalis. Notably, Dr. Isotani leads the prospective multi-institutional ROBOHIT trial, evaluating long-term outcomes for renal hilar tumors. His innovative hybrid approach to neobladder construction further underscores his commitment to refining surgical techniques for better patient recovery.